Professor of Pharmaceutics University of Florida College of Pharmacy Gainesville, Florida
This symposium topic 4 is part of the 2-hour symposium session titled “Advancing Discovery and Development of Respiratory Medicines through Emerging Technologies”. The development of respiratory medicines requires a deep understanding of the underlying biology and pharmacology of the respiratory system. Quantitative modelling is a powerful tool that can help pharmaceutical scientists to better understand how drugs interact with the respiratory system and predict their efficacy and safety.
In this symposium talk, we will cover the application of quantitative modelling in the development of respiratory medicines. We will begin by providing an overview of the different types of quantitative modelling techniques that can be used in this context, including pharmacokinetic (PK) and pharmacodynamic (PD) modelling, physiologically-based PK modelling (PBPK), and systems biology modelling. We will then discuss how these models can be used to optimize drug development and dosage regimens, as well as to predict drug efficacy and toxicity.
Next, we will delve into specific case studies where quantitative modelling has been used to aid in the development of respiratory medicines. We will discuss how PBPK modelling has been used to predict the systemic exposure of inhaled drugs and how PD modelling has been used to optimize drug dosing and delivery. We will also cover the use of PK/PD modelling in the development of combination therapies and the use of systems biology modelling to predict the impact of genetic variation on drug response.
We will also address some of the challenges associated with quantitative modelling in the development of respiratory medicines. This will include a discussion of the limitations of current models and the need for more complex and accurate models, as well as the challenges associated with integrating data from different sources into a cohesive model.
Finally, we will discuss the future of quantitative modelling in the development of respiratory medicines. We will explore how the development of new technologies, such as artificial intelligence and machine learning, can help to improve the accuracy and predictiveness of quantitative models. We will also discuss the potential of personalized medicine and precision dosing, and how quantitative modelling can aid in the development of these approaches.
Overall, this symposium talk will provide attendees with a comprehensive overview of the application of quantitative modelling in the development of respiratory medicines. By showcasing specific case studies and discussing the challenges and opportunities associated with these models, attendees will gain a deep understanding of how quantitative modelling can be used to improve the development of respiratory medicines and ultimately improve patient outcomes.
Learning Objectives:
Describe the principles and methodologies of quantitative modeling in respiratory medicine development.
Discuss the potential applications of quantitative modeling in optimizing drug dosing and delivery strategies for respiratory diseases.
Describe the current and future trends in the use of quantitative modeling in respiratory medicine development.